Cadence Pharmaceutical (CADX +2%) moves up after beating Q4 estimates across the board. Total...
Cadence Pharmaceutical (CADX +2%) moves up after beating Q4 estimates across the board. Total revenue rose over 180% Y/Y, driven by higher licensing revenue driven by it's data license agreement with Terumo Corporation. Terumo intends to seek regulatory approval in Japan for the same intravenous formulation of acetaminophen as CADX's Ofirmev.
Check out Seeking Alpha’s new Earnings Center »
From other sites
at Nasdaq.com (Apr 9, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs